22NW LP’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,467,300
| Closed | -$84.8M | – | 17 |
|
|
2025
Q4 | $84.8M | Hold |
15,467,300
| – | – | 35.68% | 1 |
|
|
2025
Q3 | $38.7M | Hold |
15,467,300
| – | – | 18.22% | 1 |
|
|
2025
Q2 | $22.3M | Hold |
15,467,300
| – | – | 14.03% | 3 |
|
|
2025
Q1 | $20.1M | Hold |
15,467,300
| – | – | 13.49% | 3 |
|
|
2024
Q4 | $26M | Buy |
15,467,300
+10,101,010
| +188% | +$16.6M | 16.39% | 3 |
|
|
2024
Q3 | $10.4M | Hold |
5,366,290
| – | – | 8.68% | 5 |
|
|
2024
Q2 | $14.6M | Hold |
5,366,290
| – | – | 12.5% | 3 |
|
|
2024
Q1 | $15.4M | Hold |
5,366,290
| – | – | 13.27% | 2 |
|
|
2023
Q4 | $13M | Buy |
5,366,290
+300,000
| +6% | +$706K | 8.46% | 4 |
|
|
2023
Q3 | $15.5M | Hold |
5,066,290
| – | – | 11.03% | 4 |
|
|
2023
Q2 | $11.9M | Hold |
5,066,290
| – | – | 7.44% | 6 |
|
|
2023
Q1 | $14.7M | Hold |
5,066,290
| – | – | 9.03% | 4 |
|
|
2022
Q4 | $12.3M | Hold |
5,066,290
| – | – | 6.63% | 5 |
|
|
2022
Q3 | $14.2M | Buy |
5,066,290
+1,703,577
| +51% | +$6.05M | 8.02% | 4 |
|
|
2022
Q2 | $17.5M | Hold |
3,362,713
| – | – | 9.28% | 2 |
|
|
2022
Q1 | $23.8M | Hold |
3,362,713
| – | – | 8.64% | 1 |
|
|
2021
Q4 | $20.7M | Buy |
3,362,713
+19,148
| +0.6% | +$127K | 6.4% | 5 |
|
|
2021
Q3 | $21.9M | Hold |
3,343,565
| – | – | 6.52% | 3 |
|
|
2021
Q2 | $22.8M | Buy |
+3,343,565
| New | +$24.9M | 6.13% | 3 |
|
22NW LP's ANEB Position: Q1 2026 in Review
22NW LP sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 15,467,300 shares — an estimated $84.8M sold.
22NW LP first reported a position in ANEB in Q2 2021 and held it in 19 quarters. The position peaked at $84.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- 22NW LP reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- 22NW LP sold 15,467,300 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $84.8M.
- 22NW LP first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- 22NW LP's Anebulo Pharmaceuticals position peaked at $84.8M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on 22NW LP's 13F filing for Q1 2026, filed 15 May 2026.